



# Cmp 3,828.70



# Target 5,450



- ❖ Larsen & Toubro Limited (L&T) is India's leading engineering and infrastructure conglomerate with global operations in over 50 countries. With a legacy of over 80 years, L&T has played a key role in building India's core infrastructure while maintaining strong governance, innovation, and operational excellence.
- ❖ In FY25, L&T reported record consolidated revenue of over ₹2.1 lakh crore, reflecting healthy year-on-year growth, supported by robust execution across infrastructure, energy, and services businesses. The company achieved a PAT of around ₹15,000 crore, backed by strong order inflows and efficient cost management.
- ❖ The infrastructure segment remained the main growth driver, contributing nearly 75% of the order inflows, while the energy, hi-tech manufacturing, and IT services divisions continued to strengthen the group's diversified portfolio.
- L&T's order book reached an all-time high, driven by domestic infrastructure demand, energy transition projects, and international EPC opportunities. The company's focus on green hydrogen, renewables, digital solutions, and smart manufacturing underlines its commitment to sustainable growth.
- ❖ With a strong balance sheet, strategic capital allocation, and rising public and private capex, L&T is well-positioned for continued expansion. We maintain a positive outlook on the company given its execution capabilities, diversified business model, and leadership in India's infrastructure and engineering space.


STOCK DATA	
NSE code	LT
Market Cap	₹ 5,26,102 Cr
High / Low	₹ 3,964 / 2,965
Stock P/E	33.8
Avg Vol 1Mth	20,76,477
Debt	1,32,409
ROE	16.6 %
























#### Cmp 1,868.70



### Target 2,750



- ❖ C.E. Info Systems Ltd. (MapmyIndia) is India's leading digital mapping and geospatial technology company, providing location-based solutions to automotive, logistics, government, and enterprise clients.
- In FY25, the company reported a 22% YoY revenue growth to ₹463 crore, with EBITDA rising 15% to ₹180 crore and PAT up 10% to ₹148 crore.
- ❖ The company declared a ₹3.50 per share dividend and ended the year with cash & investments of ₹660 crore and an order book of over ₹1,500 crore, ensuring strong revenue visibility.
- In Q4 FY25, revenue surged 34% YoY to ₹143 crore, with PAT of ₹49 crore and an EBITDA margin of ~40%, driven by robust growth in map-led and IoT businesses.Q1 FY26 also saw consistent performance with ₹122 crore revenue (+21% YoY) and ₹46 crore PAT (+28% YoY), reflecting sustained demand in SaaS and mobility platforms.
- MapmyIndia continues to invest in 3D mapping, drone tech, autonomous navigation, and EV ecosystem solutions, aligning with India's digital and smart infrastructure growth. With a scalable, asset-light model, strong profitability, and leadership in the geospatial sector, the company aims to cross ₹1,000 crore revenue by FY28.
- We maintain a positive outlook on MapmyIndia given its technology leadership, recurring revenue base, and strong position in India's growing digital economy.


STOCK DATA		
NSE code	MAPMYINDIA	
Market Cap	₹ 10,200 Cr.	
High / Low	₹ 2,204 / 1,513	
Stock P/E	64.8	
Avg Vol 1Mth	3,69,273	
Debt	29.8 Cr.	
ROE	_17.6 %	























# Cmp 7,826




# Target 10,200



- Apollo Hospitals Enterprise Ltd. stands as India's largest and most diversified healthcare provider, integrating hospitals, diagnostics, pharmacies, and digital health under one platform.
- In FY25, Apollo reported ₹21,794 crore in revenue (+14% YoY), EBITDA of ₹3,022 crore (+26%), and PAT of ₹1,446 crore (+61%), reflecting robust growth and superior operating leverage.
- ❖ The company operates over 10,000 beds, with a roadmap to add 4,300+ beds through an ₹8,000 crore expansion plan, reinforcing its dominance in high-end tertiary and quaternary care.
- In Q1 FY26, Apollo delivered ₹5,842 crore revenue and ₹433 crore PAT, supported by improved occupancy, higher ARPOB, and increasing digital revenue contribution. Compared to peers like Fortis Healthcare (ARPOB ~₹2.1 lakh, 4,500 beds) and Narayana Health (ARPOB ~₹1.4 lakh, 6,700 beds), Apollo leads with ARPOB above ₹3.1 lakh and the most extensive pan-India presence, highlighting its superior patient mix and brand strength.
- ❖ Apollo continues to integrate Al-driven diagnostics, robotic surgery, and predictive analytics, making its operations more efficient and outcomes more precise. Its Apollo 24|7 and HealthCo platforms strengthen the company's digital footprint, enabling omnichannel healthcare delivery and expanding its recurring revenue base.
- ❖ With strong financial health, expanding capacity, and technology-led innovation, Apollo Hospitals is well-positioned for long-term growth. Backed by a **positive outlook**, scalable infrastructure, and superior profitability, the company continues to lead India's healthcare transformation with consistent performance and innovation.

























### Cmp 3,497.20



# Target 4,550



- ❖ Mahindra & Mahindra Limited (M&M) is one of India's leading conglomerates with a strong presence across automotive, farm equipment, financial services, IT, real estate, and renewable energy sectors. Over eight decades, M&M has evolved into a globally respected organization known for innovation, sustainability, and stakeholder value creation.
- ❖ M&M reported a record revenue of ₹1,59,211 crore, a 14% year-on-year growth, with net profit rising 20% to ₹12,929 crore, reflecting strong performance across businesses.
- ❖ The automotive division strengthened its leadership with a 22.5% SUV revenue market share, supported by blockbuster launches like Thar ROXX, XUV 3XO, and Electric Origin SUVs (BE 6 & XEV 9e). The farm equipment segment maintained its No.1 position with a 43.3% market share, marking the 42nd consecutive year of leadership.
- M&M is driving its next phase of growth through electric mobility, farm mechanization, renewable energy, and digital transformation. Its subsidiaries Tech Mahindra, Mahindra Finance, Lifespaces, and Susten continue to deliver strong operational and financial performance.
- ❖ With a focus on sustainability, technological advancement, and disciplined capital allocation, Mahindra & Mahindra is well-positioned for long-term growth. We hold a positive outlook on the company given its diversified business model, strong execution, and leadership in key growth sectors like EVs, agriculture, and green energy.


STOCK DATA	
NSE code	M&M
Market Cap	₹ 4,34,738Cr.
High / Low	₹ 3,724 / 2,360
Stock P/E	31.6
Avg Vol 1Mth	22,21,476
Debt	₹ 1,29,025 Cr.
ROE	18.0 %
























### Cmp 886.10




#### Target 1,150



- ❖ State Bank of India (SBI) is India's largest public sector bank, with a dominant presence across retail, corporate, and digital banking.
- In FY25, SBI reported a net profit of ₹70,901 crore (+16% YoY), supported by strong credit growth and operational efficiency. The bank's CASA ratio (~45%) is among the highest in the industry, giving it a low-cost deposit advantage over peers like HDFC Bank (~42%) and ICICI Bank (~42%). Its Net Interest Margin (NIM) of 3.09% is slightly lower than private banks but reflects the benefit of scale and low-cost funding. Return on Assets (RoA) of 1.1% demonstrates efficient utilization of SBI's large balance sheet, while gross NPAs at 1.82% indicate improving asset quality.
- The cost-to-income ratio reflects strong operational efficiency, supported by digital initiatives such as YONO 2.0 and Omni-channel banking.
- ❖ SBI achieved 12% YoY loan growth, driven by retail, corporate, and priority sector lending, maintaining a balanced portfolio with prudent risk management. Compared with peers, SBI's high CASA, scale, and government backing provide financial stability, even though private banks like HDFC and ICICI maintain higher RoA and NIM.
- ❖ Digital adoption, fee income growth, and retail expansion are expected to sustain profitability and improve margins in the medium term. With robust fundamentals, improving asset quality, and technology-driven initiatives, SBI is well-positioned to benefit from India's ongoing credit growth. We maintain a positive outlook on SBI, anchored on its high CASA ratio, operational scale, and digital-led growth, making it a strong banking pick.

STOCK DATA		
NSE code	SBIN	
Market Cap	₹ 8,18,756Cr.	
High / Low	₹ 888 / 680	
Stock P/E	10.3	
Avg Vol 1Mth	1,17,85,044	
Debt	₹ 61,20,484 Cr.	
ROE	17.2 %	
























Disclaimer

This report has been prepared by ITI Securities Broking Limited (hereinafter referred to as ITISBL) to provide information about the company(ies) and/sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). ITISBL is a Stock Broker and Depository Participant registered with

and regulated by Securities & Exchange Board of India. ITISBL and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group.

This report is for personal information of the selected recipient/s and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and ITISBL is not soliciting any action based upon it. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients.. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. We and our affiliates have investment banking and other business relationships with a some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may educate investments in such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on the profitability of ITISBL which may include earnings from investment banking and other business.

ITISBL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, ITISBL generally prohibits its analysts, and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing among other things, may give rise to real or potential conflicts of interest. ITISBL and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have reported in such as a market maker in the financial instruments of the company(ies) discussed herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have a long or short positions and advisor or lender/borrower to such company(ies) discussed herein. (b) be engaged in any other transaction involving such securities and approach or company in the foreign su

Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information provided by the person accessing this information and further agrees to hold ITISBL or any of its affiliates or employees responsible for any such misuse and further agrees to hold its affiliates or employees from any such misuse and further agrees to hold its affiliates or employees from any such misuse and further agrees to hold its affiliates or employees from any such misuse and further agrees to hold its affiliates or employees from any such misuse and further agrees to hold its affiliates or employees from any such misuse and further agrees to hold its affiliates or employees from any such misuse and further agrees to hold its affiliates or employees and nor blight on the person accessing this information and/or opinions provided by that third party its affiliates or employees that may are personated to be reliable. Any statements contained in this report is intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavour to update the information herein on reasonable basis, ITISBL and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent ITISBL and/or its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information. Also there may be regulatory, compliance, or other reasons that may prevent ITISBL and/or its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information to intended to be a complete statement or prevent its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person its affiliates or employees shal

#### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of ITISBL research, investor client feedback, stock picking, competitive factors and firm revenues

#### Disclosure of Interest Statement - Companies where there is interest

Analyst ownership of the stock: No

Served as an officer, director or employee: No

#### **Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ITISBL & its group companies to registration or licensing requirements within such jurisdictions.

**ITI Securities Broking Limited** 

SEBI – Research Analyst REG. NO.: INH000001535

SEBI REG. NO: NSE&BSE: INZ000005835, CDSL-IN-DP-70-2015, AMFI Reg. No. ARN-12576

CIN NO: U74120MH1994PLC077946 ITI House, 36, Dr. R. K. Shirodkar Road, Parel, Mumbai - 400 012,

Boardline - (91) 22 69093600 Fax- 022 69093700

For gueries, write to us at iti.research@itiorg.com